Alpha cognition announces positive pre-clinical data for alpha-1062 use in a military relevant model of repetitive mild traumatic brain injury

Vancouver, british columbia & dallas--(business wire)--alpha cognition inc. (nasdaq: acog) (“alpha cognition” [aci], or the “company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data supporting the continued development of alpha-1062 for the treatment of mild traumatic brain injury (mtbi). the data provides additional evidence of benefits of alpha-1062, in the treatment of mtbi resulting from repetitive blast.
ACOG Ratings Summary
ACOG Quant Ranking